Directed Protein Degradation
Medicines That Matter
Advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins
Degradation is a powerful therapeutic modality that removes the entire disease-causing protein and associated scaffolding to drive deep and long-lasting therapeutic responses. By degrading extracellular targets, we are addressing the 40% of the proteome left behind by intracellular degradation approaches.
Our EpiTAC platform leverages a novel atlas of 270+ degradation-inducing protein receptors expressed on the surface of distinct tissue and cell types to create tissue-selective therapies against membrane and extracellular proteins.The degrader receptor localizes EpiTACs’ activity to selectively degrade disease-causing proteins, spare healthy tissue, and drive powerful efficacy for cancer, autoimmune disorders, and other serious diseases.
Clearing the path to transform people’s lives
EpiBiologics’ pioneering science and skilled team are solving challenging problems to create new therapeutic options for patients.